These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28707375)

  • 61. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
    Xu B; Dou K; Yang Y; Lv S; Wang L; Wang H; Li Z; Wang L; Chen Y; Huo Y; Li W; Kirtane AJ; Gao R
    EuroIntervention; 2012 Nov; 8(7):796-802. PubMed ID: 23171800
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up.
    Wiemer M; Stoikovic S; Samol A; Dimitriadis Z; Ruiz-Nodar JM; Birkemeyer R; Monsegu J; Finet G; Hildick-Smith D; Tresukosol D; Novo EG; Koolen JJ; Barbato E; Danzi GB;
    Cardiovasc Diabetol; 2017 Feb; 16(1):23. PubMed ID: 28183306
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
    Vardi M; Burke DA; Bangalore S; Pencina MJ; Mauri L; Kandzari DE; Leon MB; Cutlip DE
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1031-8. PubMed ID: 23737390
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: 5-year results of the TARGET Ⅱ trial].
    Xu LJ; Gao Z; Song Y; Wang HH; Xu JJ; Gao LJ; Zhang Y; Song L; Zhao XY; Chen J; Yuan JQ; Qiao SB; Yang YJ; Xu B; Gao RL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Jul; 46(7):523-528. PubMed ID: 30032542
    [No Abstract]   [Full Text] [Related]  

  • 68. The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes.
    Verheye S; Vrolix M; Kumsars I; Erglis A; Sondore D; Agostoni P; Cornelis K; Janssens L; Maeng M; Slagboom T; Amoroso G; Jensen LO; Granada JF; Stella P
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2029-2037. PubMed ID: 28964764
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Paclitaxel- and sirolimus-eluting stents in older patients with diabetes mellitus: results of a real-life multicenter registry.
    Buja P; Facchin M; Musumeci G; Frigo AC; Saia F; Menozzi A; Meliga E; Sardella G; Tamburino C; Tarantini G
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1117-24. PubMed ID: 22936398
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial.
    Chevalier B; Dimario C; Neumann FJ; Cutlip DE; Williams DO; Ormiston J; Grube E; Whitbourn R; Coe J; Schwartz LB;
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1039-47. PubMed ID: 23592567
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients.
    Sinha N; Rai H; Cassese S; Kumar S; Kapoor A; Kastrati A
    Coron Artery Dis; 2016 Aug; 27(5):385-90. PubMed ID: 27124380
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of Insulin-Treated and Noninsulin-Treated Diabetes Mellitus in All-Comer Patients Undergoing Percutaneous Coronary Interventions With Polymer-Free Biolimus-Eluting Stent (from the RUDI-FREE Registry).
    Pepe M; Sardella G; Stefanini GG; Corcione N; Nestola PL; Morello A; Briguori C; Tamburino C; Fabbiocchi F; Rotolo FL; Tomai F; Paggi A; Lombardi M; Gioffrè G; Sclafani R; Rolandi A; Sciahbasi A; Scardaci F; Signore N; Mancone M; Giordano A
    Am J Cardiol; 2019 Nov; 124(10):1518-1527. PubMed ID: 31547997
    [TBL] [Abstract][Full Text] [Related]  

  • 73. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions.
    Wang XZ; Zhang YJ; Fu GS; Jing QM; Xu B; Han YL
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):617-622. PubMed ID: 29392879
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
    Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
    Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry.
    Dai Y; Wang R; Chen F; Zhang Y; Liu Y; Huang H; Yang P; Zhang R; Zheng B; Gao C; Chen Y; Tao L
    BMC Cardiovasc Disord; 2021 Nov; 21(1):537. PubMed ID: 34772347
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
    Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
    Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K; Niemelä M; Romppanen H; Erglis A; Kumsars I; Maeng M; Holm NR; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Helqvist S; Vikman S; Wiseth R; Aarøe J; Jokelainen J; Thuesen L;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1160-5. PubMed ID: 24262616
    [TBL] [Abstract][Full Text] [Related]  

  • 79. First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial.
    Yu M; Xu B; Kandzari DE; Wu Y; Yan H; Chen J; Qian J; Qiao S; Yang Y; Gao RL
    Catheter Cardiovasc Interv; 2014 Feb; 83(3):405-11. PubMed ID: 23857821
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.
    Rola P; Włodarczak A; Barycki M; Szudrowicz M; Łanocha M; Kulczycki JJ; Turkiewicz K; Woźnica K; Lesiak M; Doroszko A
    J Diabetes Res; 2021; 2021():8636050. PubMed ID: 34859105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.